The round was led by new investor Frazier Life Sciences, with participation from F-Prime, Qiming Venture Partners, SR One and founding investors Cambridge Innovation Capital and Cambridge Enterprise Ventures.
The proceeds from this financing will fund Immutrin’s lead asset through clinical proof of concept in ATTR cardiomyopathy, a serious and often fatal form of amyloidosis.
Amyloidosis is a group of rare, progressive diseases caused by misfolded proteins that aggregate into amyloid fibrils and accumulate in tissues and organs, leading to irreversible organ damage. While recent therapeutic advances slow or suppress amyloid production, no approved therapies effectively remove pre-existing amyloid deposits, leaving the underlying pathology largely intact. Effective amyloid removal is widely regarded as critical to restoring organ function and improving long-term clinical outcomes.